Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous expanded adipose-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- FIBHULP
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
Autologous expanded adipose-derived mesenchymal stem cells (ADMSCs) is an investigational somatic cell therapy developed by the Fundación para la Investigación Biomédica del Hospital Universitario La Paz in Spain. The therapy involves harvesting a patient's own mesenchymal stem cells from adipose tissue via liposuction, followed by ex vivo expansion in a laboratory setting and subsequent endoscopic intraurethral (periurethral or intrasphincteric) injection. It is primarily being evaluated for the treatment of urinary incontinence following radical prostatectomy. The mechanism of action is thought to involve the regeneration and repair of the urethral sphincter and surrounding pelvic tissues through paracrine signaling, including the release of trophic, anti-inflammatory, and pro-angiogenic factors that promote tissue restoration and functional recovery.
- Other names
- ADMSCsautologous expanded adipose-derived stem cells
Beyond the preview
Go deeper on autologous expanded adipose-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous expanded adipose-derived mesenchymal stem cells.